Literature DB >> 17019897

Interrater reliability of the Psychiatric Research Interview for Substance and Mental Disorders in an HIV-infected cohort: experience of the National NeuroAIDS Tissue Consortium.

S Morgello1, C E Holzer, E Ryan, C Young, M Naseer, S A Castellon, A B Frol, J Hampton Atkinson, B B Gelman, I Grant, E J Singer.   

Abstract

The interrater reliability of the Psychiatric Research Interview for Substance and Mental Disorders (PRISM) was assessed in a multicentre study. Four sites of the National NeuroAIDS Tissue Consortium performed blinded reratings of audiotaped PRISM interviews of 63 HIV-infected patients. Diagnostic modules for substance-use disorders and major depression were evaluated. Seventy-six per cent of the patient sample displayed one or more substance-use disorder diagnoses and 54% had major depression. Kappa coefficients for lifetime histories of substance abuse or dependence (cocaine, opiates, alcohol, cannabis, sedative, stimulant, hallucinogen) and major depression ranged from 0.66 to 1.00. Overall the PRISM was reliable in assessing both past and current disorders except for current cannabis disorders when patients had concomitant cannabinoid prescriptions for medical therapy. The reliability of substance-induced depression was poor to fair although there was a low prevalence of this diagnosis in our group. We conclude that the PRISM yields reliable diagnoses in a multicentre study of substance-experienced, HIV-infected individuals.

Entities:  

Mesh:

Year:  2006        PMID: 17019897      PMCID: PMC6878302          DOI: 10.1002/mpr.189

Source DB:  PubMed          Journal:  Int J Methods Psychiatr Res        ISSN: 1049-8931            Impact factor:   4.035


  26 in total

1.  Concurrent and predictive validity of the Substance Dependence Severity Scale (SDSS).

Authors:  G M Miele; K M Carpenter; M Smith Cockerham; K Dietz Trautman; J Blaine; D S Hasin
Journal:  Drug Alcohol Depend       Date:  2000-04-01       Impact factor: 4.492

2.  Inter-rater reliability of the SCID alcohol and substance use disorders section among adolescents.

Authors:  C S Martin; N K Pollock; O G Bukstein; K G Lynch
Journal:  Drug Alcohol Depend       Date:  2000-05-01       Impact factor: 4.492

3.  Reliability of diagnosis in mood disorders.

Authors:  C E Holzer; H T Nguyen; R M Hirschfeld
Journal:  Psychiatr Clin North Am       Date:  1996-03

4.  A validity study of the SSAGA--a comparison with the SCAN.

Authors:  M Hesselbrock; C Easton; K K Bucholz; M Schuckit; V Hesselbrock
Journal:  Addiction       Date:  1999-09       Impact factor: 6.526

5.  Changes in depressive symptoms as AIDS develops. The Multicenter AIDS Cohort Study.

Authors:  C G Lyketsos; D R Hoover; M Guccione; M A Dew; J E Wesch; E G Bing; G J Treisman
Journal:  Am J Psychiatry       Date:  1996-11       Impact factor: 18.112

6.  Multidisciplinary baseline assessment of homosexual men with and without human immunodeficiency virus infection. II. Standardized clinical assessment of current and lifetime psychopathology.

Authors:  J B Williams; J G Rabkin; R H Remien; J M Gorman; A A Ehrhardt
Journal:  Arch Gen Psychiatry       Date:  1991-02

7.  Depressive and anxiety disorders in women with HIV infection.

Authors:  Mary F Morrison; John M Petitto; Thomas Ten Have; David R Gettes; Margaret S Chiappini; Anita L Weber; Priscilla Brinker-Spence; Russell M Bauer; Steven D Douglas; Dwight L Evans
Journal:  Am J Psychiatry       Date:  2002-05       Impact factor: 18.112

8.  The National NeuroAIDS Tissue Consortium: a new paradigm in brain banking with an emphasis on infectious disease.

Authors:  S Morgello; B B Gelman; P B Kozlowski; H V Vinters; E Masliah; M Cornford; W Cavert; C Marra; I Grant; E J Singer
Journal:  Neuropathol Appl Neurobiol       Date:  2001-08       Impact factor: 8.090

9.  Diagnostic interview for genetic studies (DIGS): inter-rater and test-retest reliability of alcohol and drug diagnoses.

Authors:  Alexandre Berney; Martin Preisig; Marie-Louise Matthey; François Ferrero; Brenda T Fenton
Journal:  Drug Alcohol Depend       Date:  2002-01-01       Impact factor: 4.492

10.  WHO Neuropsychiatric AIDS study, cross-sectional phase I. Study design and psychiatric findings.

Authors:  M Maj; R Janssen; F Starace; M Zaudig; P Satz; B Sughondhabirom; M A Luabeya; R Riedel; D Ndetei; H M Calil
Journal:  Arch Gen Psychiatry       Date:  1994-01
View more
  16 in total

1.  Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy.

Authors:  I Everall; F Vaida; N Khanlou; D Lazzaretto; C Achim; S Letendre; D Moore; R Ellis; M Cherner; B Gelman; S Morgello; E Singer; I Grant; E Masliah
Journal:  J Neurovirol       Date:  2009-09       Impact factor: 2.643

2.  Alcohol dependence and suicide-related ideation/behaviors in an Israeli household sample, with and without major depression.

Authors:  Gal Shoval; Dvora Shmulewitz; Melanie M Wall; Efrat Aharonovich; Baruch Spivak; Avraham Weizman; Deborah Hasin
Journal:  Alcohol Clin Exp Res       Date:  2013-10-07       Impact factor: 3.455

3.  Factors related to HIV-associated neurocognitive impairment differ with age.

Authors:  Gary B Fogel; Susanna L Lamers; Andrew J Levine; Miguel Valdes-Sueiras; Michael S McGrath; Paul Shapshak; Elyse J Singer
Journal:  J Neurovirol       Date:  2014-11-18       Impact factor: 2.643

4.  Measures of Physical and Mental Independence Among HIV-Positive Individuals: Impact of Substance Use Disorder.

Authors:  Bianca Christensen; Zijian Qin; Desiree A Byrd; Fang Yu; Susan Morgello; Benjamin B Gelman; David J Moore; Igor Grant; Elyse J Singer; Howard S Fox; Lorena Baccaglini
Journal:  AIDS Res Hum Retroviruses       Date:  2017-04-10       Impact factor: 2.205

5.  Major depressive disorder, cognitive symptoms, and neuropsychological performance among ethnically diverse HIV+ men and women.

Authors:  Robert P Fellows; Desiree A Byrd; Susan Morgello
Journal:  J Int Neuropsychol Soc       Date:  2013-01-04       Impact factor: 2.892

6.  Neurovirological correlation with HIV-associated neurocognitive disorders and encephalitis in a HAART-era cohort.

Authors:  Benjamin B Gelman; Joshua G Lisinicchia; Susan Morgello; Eliezer Masliah; Deborah Commins; Cristian L Achim; Howard S Fox; Dennis L Kolson; Igor Grant; Elyse Singer; Constantin T Yiannoutsos; Seth Sherman; Gary Gensler; David J Moore; Tiansheng Chen; Vicki M Soukup
Journal:  J Acquir Immune Defic Syndr       Date:  2013-04-15       Impact factor: 3.731

7.  HIV DNA Is Frequently Present within Pathologic Tissues Evaluated at Autopsy from Combined Antiretroviral Therapy-Treated Patients with Undetectable Viral Loads.

Authors:  Susanna L Lamers; Rebecca Rose; Ekaterina Maidji; Melissa Agsalda-Garcia; David J Nolan; Gary B Fogel; Marco Salemi; Debra L Garcia; Paige Bracci; William Yong; Deborah Commins; Jonathan Said; Negar Khanlou; Charles H Hinkin; Miguel Valdes Sueiras; Glenn Mathisen; Suzanne Donovan; Bruce Shiramizu; Cheryl A Stoddart; Michael S McGrath; Elyse J Singer
Journal:  J Virol       Date:  2016-09-29       Impact factor: 5.103

8.  Test-retest reliability of DSM-5 substance disorder measures as assessed with the PRISM-5, a clinician-administered diagnostic interview.

Authors:  Deborah Hasin; Dvora Shmulewitz; Malka Stohl; Eliana Greenstein; Stephanie Roncone; Efrat Aharonovich; Melanie Wall
Journal:  Drug Alcohol Depend       Date:  2020-09-15       Impact factor: 4.492

9.  An exploratory study of long-term neurocognitive outcomes following recovery from opportunistic brain infections in HIV+ adults.

Authors:  Andrew J Levine; Charles H Hinkin; Kazuhiro Ando; Gianni Santangelo; Mariana Martinez; Miguel Valdes-Sueiras; Ernestina H Saxton; Glen Mathisen; Deborah L Commins; Ardis Moe; Charles Farthing; Elyse J Singer
Journal:  J Clin Exp Neuropsychol       Date:  2008-02-08       Impact factor: 2.475

10.  Prefrontal dopaminergic and enkephalinergic synaptic accommodation in HIV-associated neurocognitive disorders and encephalitis.

Authors:  Benjamin B Gelman; Joshua G Lisinicchia; Tianshen Chen; Kenneth M Johnson; Kristofer Jennings; Daniel H Freeman; Vicki M Soukup
Journal:  J Neuroimmune Pharmacol       Date:  2012-03-06       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.